JOGO Health provides virtual care solutions for managing chronic pain and neuromuscular conditions. Its flagship product, JOGO-Gx, is an AI-driven mobile app that integrates with wearable sensors that leverage electromyography (EMG) biofeedback therapy. This approach enables patients to gain insights into their muscle systems and learn to control muscle tension effectively, promoting pain reduction.
The company's core technology leverages the principles of neuroplasticity, which refers to the brain's ability to reorganize its neural pathways. By training the brain to relax through biofeedback, JOGO-Gx helps patients manage conditions like chronic lower back pain, Parkinson's disease tremors, and cancer pain. Its products do not emit electrical signals, making them non-invasive.
In 2020, the FDA granted a 510(k) exemption for JOGO-Gx, enabling broader access to its virtual EMG biofeedback solutions. Furthermore, in May 2023, JOGO Health received the FDA's breakthrough device designation for its JOGO-CLBP product.
Key customers and partnerships
As of June 2024, the company had treated over 25,000 patients worldwide across over 50 hospital partners, including Mayo Clinic and Mount Sinai.
In July 2024, JOGO Health partnered with Mayo Clinic to study Parkinson's tremors, functional tremors, and essential tremors using JOGO Health's digital platform.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.